20035-44-3

Usage

InChI:InChI=1/C9H9BrO3/c1-2-13-8-4-7(10)3-6(5-11)9(8)12/h3-5,12H,2H2,1H3

Upstream product

• 24677-78-9 2,3-dihydroxybenzaldehyde 
• 492-88-6 3-ethoxysalicylaldehyde 
• 7726-95-6 bromine 
• 127-09-3 sodium acetate 
• 64-19-7 acetic acid 

Downstream Products

• 35093-67-5 5-Brom-o-bourbonalsaeure 
• 35090-67-6 5-Brom-o-bourbonylalkohol 
• 861787-33-9 3-ethoxy-5-bromo-2-methoxy-benzaldehyde 
• 861302-91-2 2,3-diethoxy-5-bromo-benzaldehyde 

Relevant academic research and scientific papers

3-substituted coumarin derivatives and their use

The invention provides a 3-substituted coumarin derivative, and pharmaceutically acceptable salts, solvates, hydrates or crystal forms thereof. The above compound has a high calcium flow activity and a very good selectivity on a human derived cannabinoid receptor CB2, and is a specific agonist or inverse agonist of the cannabinoid receptor CB2. The compound is an active ligand of a novel cannabinoid II receptor CB2, and compounds of the above kind and pharmaceutically acceptable salts, solvates, hydrates or crystal forms thereof have high calcium flow activities and a very good selectivity on the human derived cannabinoid receptor CB2. The compound is the specific agonist or inverse agonist of the cannabinoid receptor CB2, and can be applied to the preparation of medicines for treating, preventing and inhibiting CB2 receptor mediated diseases. The structure of the derivative is represented by a general formula A shown in the specification.

BENZOPYRAN COMPOUNDS USEFUL FOR TREATING INFLAMMATORY CONDITIONS

The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with cyclooxygenase-2 mediated disorders. Compounds of particular interest are benzopyrans and their analogs defined by formula (1). Wherein Z, X, R1, R2, R3, and R4 are as described in specification.

CHROMENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS

The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with cyclooxygenase-2 mediated disorders. Compounds of particular interest are benzopyrans and their analogs defined by formula (I). Wherein Z, X, R1, R2, R3, and R4 are as described in the specification.